SITEMAN INVESTMENT PROGRAM

Karen Kharasch, Executive Director

SITEMAN CANCER CENTER

Disclosure Information

I have no financial relationships to disclose.

2015 CCAF Annual Meeting

SITEMAN INVESTMENT PROGRAM

Barnard Trust

PI Members

Grants awarded

Programs NCI & NIH

Other Peer Review

Non Peer Reviewed

SITEMAN CANCER CENTER

4

83107

7

$ 39.2 million 71 Leveraged grants

$12.4 millionSIP awarded grants

45%32

4%

51%

3

36

Siteman Investment Program (SIP)2009 – 2014

PROFILE

SITEMAN CANCER CENTER

Evaluation of RFAs and Review Process

• 5 annual scientific review committees

• Extreme difficulty finding reviewers

• Faculty feedback:– Uncertain what the reviewers/Senior Leadership wants– Transparency– Consistency of announcement

• Competitive renewals for all 2 year awards

Difficulties

5

SITEMAN CANCER CENTER

New SIP Model

The following current Siteman RFAs will now be incorporated into the new review model

– SCC Research Development Awards (RDA) – Breast Cancer Program Career Development (CDA) – Breast Research Development Awards– Cancer Frontier Fund (CFF) – ACS-IRG will be a sub-study section

Streamline & Transparent

SITEMAN CANCER CENTER

Assumptions

Total awards are dependent on philanthropy – The number of awards and the award amount may increase

or decrease each year dependent on SCC philanthropy

Total awards are dependent on scientific merit – The number of awards and the award amount may increase

or decrease each year dependent on scientific merit of the applicants at each study section

SITEMAN CANCER CENTER

• Discovery, diagnosis, treatment and public health •New diagnostic tests, imaging technology, drug, vaccine,

or other cancer therapy • Accelerate discoveries to test and verify pioneering

options• Produce data that provide the basis for future applications

(such as R01s, R21s, DOD, SPOREs, PPGs, etc.) or the opportunity for business creation and venture funding• Catalyze discoveries by building bridges among disciplines

and researchers in St. Louis (WU, WUSM, SLU and soon UMSL)

Create an agile study section model in order to provide pilot funding for SCC members in discovery, diagnosis, treatment and public health

SITEMAN CANCER CENTER

Total awardfor 2 years

(direct costs)

# of awards Cycle 1 Cycle 2

Announced January 1 July 1

Due date May 1 October 1

Start date July 1 January 1

Pre-R01 $400,000 2 2

Pre-SPORE/PPG $ 800,000 1 1

Multi-PI Pre-R01 $400,000 1 1

Danforth/Consortium Pre-R01 $ 200,000 1 1

Total awarded for 2 years $ 1,800,000 5 5

SITEMAN CANCER CENTER

SIP Study Section Structure

•21 - 28 reviewers– Recommended and assigned by each program leaders– Rotating Chairs by program– Internal competition reviews as required–Ad hoc leadership: Associate Directors of Basic Science, Translation, Shared Resources and Executive Director

Representatives from all Programs

SITEMAN CANCER CENTER

SIP Study Section Structure

– Each review cycle will have 14 of the 21 reviewers – Ad hoc reviewers as required– Reviewers will serve 3 year term– Required to participate in 4 of the 6 reviews in the three year period– Rotate off after 4 study sections – Allows reviewers to take off a cycle to submit

Rotation of Reviewers

SITEMAN CANCER CENTER

Funds Allotment Review

– Chairs of the Study Section– Associate Directors of Basic, Translation Science and

Shared Resources – Executive Director– VP BJH Foundation– BJH Foundation Board member– Pedal the Cause Executive Director– Business Director

Funding Review

SITEMAN CANCER CENTER

Budget and Scientific Review

Budget–Business Director & staff have access to all Siteman

SIP accounts

Science–Scientific progress is reported once a year.

www. siteman.wustl.edu